Boardroom Alpha
S-1 primary document
CRIS · Registration Statement (Form S-1) · Filed August 10, 2026

Curis IncS-1 exhibit

exfilingfees.htm
exfilingfees
Exhibit 107
Calculation of Filing Fee Tables
Form S-1
(Form Type)
Curis, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities

Security TypeSecurity Class TitleFee Calculation or Carry Forward RuleAmount RegisteredProposed Maximum Offering Price Per UnitMaximum Aggregate Offering PriceFee RateAmount of Registration FeeCarry
Forward
Form Type
Carry
Forward
File Number
Carry
Forward
Initial
Effective
Date
Filing Fee
Previously
Paid In
Connection
with Unsold
Securities to be
Carried
Newly Registered Securities
Fees to Be Paid(1)EquityCommon Stock, $0.01 par value per share457(o)
$30,000,000.00
0.0001381 $4,143.00
Fees to Be Paid(2)EquityPre-Funded Warrants to purchase Common StockOther0.0001381
Fees to Be Paid(3)EquityCommon Warrants to purchase Common StockOther0.0001381
Fees Previously Paid
Carry Forward Securities
Carry Forward Securities
Total Offering Amounts
$30,000,000.00
$4,143.00
Total Fees Previously Paid
        
Total Fee Offsets
        
Net Fee Due$4,143.00

(1)The Maximum Aggregate Offering Price is estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the “Securities Act”). Includes shares of Common Stock issuable upon exercise of the Common Warrants and the Pre-Funded Warrants (collectively, the “Warrant Shares”). Each Pre-Funded Warrant offered in this offering will reduce the number of shares of Common Stock offered in this offering on a one-for-one basis and each share of Common Stock offered in this offering will reduce the number of Pre-Funded Warrants offered in this offering on a one-for-one basis. Pursuant to Rule 416(a) of the Securities Act, with respect to the Warrant Shares, this Registration Statement shall also cover any additional shares of Common Stock that become issuable by reason of any stock dividend, stock split, recapitalization or other similar transaction. Each Common Warrant will have an exercise price equal to 100% of the combined public offering price per share of Common Stock (or Pre-Funded Warrant in lieu thereof) and Common Warrant.

(2)In accordance with SEC guidance and Rule 457(i), the entire fee is allocated to the common stock, and no separate fee is recorded for the pre-funded warrants.

(3)In accordance with SEC guidance and Rule 457(i), the entire fee is allocated to the common stock, and no separate fee is recorded for the common warrants


Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer